readily applied in cattle for the reduction of acute inflammatory reaction in respiratory diseases (Balmer, Williams, & Selman, 1997) and further for the treatment of peracute and acute bovine mastitis (Papich, 2010) .
For this study, carprofen (±6-chloro-α-methyl-carbazole-2-acetic acid), a propionic acid derivative, was chosen for further evaluation as a potentially effective and appropriate NSAID for the use in white rhinoceros. The choice was influenced by wildlife veterinarians who reported obtaining satisfactory analgesia for 2-3 days following the administration of carprofen to rhino suffering from lameness (personal communication, Dr. J. Marais, Saving the Survivors). Furthermore, carprofen is defined by its low incidence of side effects and high therapeutic index in most veterinary species, with the possible exception of the vulture (Fourie, Cromarty, Duncan, Wolter, & Naidoo, 2015) . The wide safety margin seen in most species may be explained by the relatively weak to moderate inhibition of the COX-1 and COX-2 isoforms observed in species like the horse , calf (Delatour, Foot, Foster, Baggot, & Lees, 1996) , cat (Taylor et al., 1996) and dog (McKellar et al., 1990) given at clinically recommended drug doses.
Furthermore, carprofen exhibits excellent analgesic properties for soft tissue injuries, perioperative pain management as well as after orthopaedic procedures (Grisneaux, Pibarot, Dupuis, & Blais, 1999; Mathews, 2002) and can be administered intravenously (i.v.) intramuscularly (i.m.) as well as subcutaneously (s.c.) and per os (p.o.; McKellar, Bogan, von Fellenberg, Ludwig, & Cawley, 1991; McKellar, Delatour, & Lees, 1994; Taylor et al., 1996) . Carprofen is characterized by a low volume of distribution in steady-state of 0.093 L/kg in sheep (Welsh, Baxter, & Nolan, 1992) , 0.14 L/kg in the dog (McKellar et al., 1990) and 0.091 L/kg in the cow (Lohuis et al., 1991) . Furthermore, it is known for its long half-life of elimination in the horse (21.9 hr; McKellar et al., 1991) , the cow (30.7 hr; Lohuis et al., 1991) and sheep (26.1 hr; Welsh et al., 1992) . The clearance ranges between 0.75 ml kg −1 hr −1 in horses (McKellar et al., 1991) , 2.4 ml kg −1 hr −1 in cattle and 2.5 ml kg −1 hr −1 in sheep (Welsh et al., 1992) . When looking at the different enantiomers of the chiral drug carprofen as opposed to the total carprofen concentration, the R(−) carprofen plasma concentrations exceed those of the S(+) carprofen. Furthermore, in species such as the horse, the mean residence time and elimination half-life have been found to be three times longer for R(−) carprofen than for S(+) carprofen when administered at 0.7 mg/kg, while the clearance of the S(+) carprofen was 5.7 times more rapid . The enantiomer concentrations were found to increase in direct proportion to the administered dose. Even though quantitatively the R(−) enantiomer is predominant, the effect of racemic carprofen can be almost completely ascribed to the S(+) enantiomer (Lees, Giraudel, Landoni, & Toutain, 2004) , which is characterized by a significantly higher potency.
Due to the complexity of working with wild, endangered animals, we evaluate carprofen as it would be administered in clinical practice, which is in conjunction with an antimicrobial, while the animals are immobilized.
| MATERIAL S AND ME THODS

| Animals
The study proposal was reviewed and approved by the Animal Ethics Committee of the University of Pretoria (Approval number:
V074-15). Six white rhinoceros, one female and five males from "The Rhino Orphanage" in South Africa, were included in the study. The animals were between 15 and 30 months old, weighing in average 670 (538-902) kg. The detailed characteristics of the rhinoceros are summarized in Table 1 . Details on the living conditions, daily feeds and the habituation of the animals to the touching of their ears are presented in a previous study on the pharmacokinetics of the concurrently administered enrofloxacin.
| Experimental design and sampling procedure
Six white rhinoceros received a single i.m. injection of racemic car- clinical use but also allowed for the maximum use of the study animals, which are not easy to source and work with.
The carprofen and thromboxane B 2 (TXB 2 ) plasma concentrations were evaluated over a period of roughly 72 hr from a maximum of 11 blood samples per animal. The blood samples were taken prior to the drug administration and in average after 4.68, 18.45, 31.1, 45.77 min and 2.11, 6.17, 11.87, 22.8, 47.65, 73 .07 hr postcarprofen injection. A total of 18 ml of blood was collected in lithium heparin tubes and partly used for the analysis of the carprofen plasma concentration. Additional 2-4 ml of blood was collected in indometha- 
| Immobilization of the rhinoceros
The placement of the auricular catheter, the administration of the drugs and the first five blood samples were not possible without chemical immobilization of the animals. Thus, the six rhinoceros were sedated using a mixture of etorphine (M99, 9.8 mg/ml, Novartis) and thiafentanil (Thianil, 10 mg/ml, Wildlife Pharmaceuticals RSA).
All rhinos also received 50 mg of zuclopenthixol acetate (ClopixolAcuphase, 50 mg/ml) within 2.5 hr of the initial immobilization.
Diprenorphine (M5050, 12 mg/ml, Novartis) was given at a dose of 0.2 or 0.5 mg during the immobilization to improve the breathing and at a higher dose of 5 mg per animal at the end of the immobilization as a partial reversal, if necessary. Additionally, medetomidine (20 mg/ ml, Kyron RSA) and ketamine (50 mg/ml, Kyron RSA) were used to improve anaesthetic depth when needed. The details of the sedation of each individual are summarized in Table S1 . The blood samples scheduled at 24, 48 and 72 hr were collected under a low-dose butorphanol (Dolorex, MSD animal health, 10 mg/ml) based standing sedation directly from the cephalic vein. The details regarding the butorphanol based low-dose sedation are summarized in Table S2 . The plasma samples were mixed with the internal standard carprofen-d 3 and deproteinized. Therefore, 100 μl of plasma was added to 900 μl of a mixture containing 100 ml of 0.40 g ammonium acetate in 1L water, 1 ml formic acid and 600 ml acetonitrile. The samples were placed on a vibratory mixer for 30 s prior to centrif-
ugation. An aliquot of 5 μl was then injected into the HPLC system.
The chromatographic separation was performed with a ZORBAX SB Phenyl column, 2.1 × 50 mm, 1.8 μm (Agilent Technologies, Waldbronn, Germany) using the mobile phase A (water, 10 mm ammonium formate and 0.12 ml/L formic acid) and the mobile phase B (methanol, 10 mm ammonium formate, and 0.12 ml/L formic acid).
Gradient elution with a flow rate of 0.5 ml/min started at 10% B for 0.5 min, eluent strength was then increased and, after 1.5 min, reached 95% B for 1 min. Thereafter, the eluent strength decreased to 10% B after 3 min and was equilibrated for 1 min. The quantitative determination was performed by HPLC with detection by tandem mass spectrometry using an API 5500 mass spectrometer (Sciex, Darmstadt, Germany). The retention time for carprofen was 1.7 min. Carprofen was detected in the positive ionization mode using the transition from its precursor ion at m / z 274 to its product ion at m / z 228 or m / z 193. The internal standard carprofen-d 3 was detected in the positive ionization mode using the transition from its precursor ion at m / z 277 to its product ion at m / z 231. The limit of quantification was 0.01 mg/L. As the amount of available rhino control plasma was limited, the method validation was performed using four validation levels (0.01/0.1/1/10 μg/ml) with three replicates each. The mean recovery rates for the individual fortification levels were between 81% and 97%. The mean overall was 93%,
representing an accuracy of −7% with a precision (coefficient of variation) of 10%. The method is a variation of our routine plasma method and shows a high specificity as a result of the selective determination by tandem mass spectrometry. Matrix effects are compensated by the use of an internal standard. The limit of detection was set to the lowest standard concentration used for the measurement, which corresponds to 0.005 μg/ml.
| Thromboxane B2 analysis
The inhibition of TXB 2 , the stable metabolite of thromboxane A 2 (TXA 2 ), was used as an indicator for the extent and the timedependent course/duration of COX-1 inhibition .
The "Thromboxane B2 Express EIA Kit -Monoclonal" (Cayman Chemical) was used to measure the TXB 2 concentrations in the plasma. Plasma samples were purified prior to TXB 2 analysis via ELISA, and all procedures were carried out according to the instructions provided by Cayman Chemical. Briefly, the concentration of TXB 2 from the plasma sample binding to a limited amount of TXB 2 -specific antibodies in the well determines the intensity of the enzymatic reaction, which is assessed photo spectrometrically (410 nm).
For the calculation of the TXB 2 concentrations based on the absorbance readings, a standard curve was generated with eight standards of known concentrations. The ratio of standard bound/ maximal bound (B/B0) for all standards was plotted against the TXB 2 concentration as a semi-logarithmic plot and a linear visual fit was carried out. With the equation generated from the standard curve and the B/B0 ratio (sample bound/maximal bound) of each sample, the TXB 2 concentration of each plasma sample was calculated.
| Pharmacokinetic analysis
All pharmacokinetic parameters were calculated with Kinetica 5.0 (Thermo) using a noncompartmental model. The maximum plasma concentration (C max ) and the time to maximum concentration (T max ) were read directly of the concentration versus time plasma profile. The area under curve to the last quantifiable time point (AUC last ) was determined using the linear trapezoidal rule
The total area under curve extrapolated to infinity (AUC tot ) was calculated as AUC tot = AUC last + AUC extra = AUC last + C Last /λ with C last being the computed last measured concentration and λ being the terminal elimination rate constant. The area under the moment curve from the time point zero to the last measured time point (AUCM last ) was calculated 
| RE SULTS
| Side effects
No adverse effects were observed at the site of injection after carprofen administration. All six rhinoceros ate within 12 hr after immobilization and displayed normal physiological behaviour. In four of six animals, a band like swelling was observed at the base of the ear in which the intravenous enrofloxacin was administered. The adverse reaction appeared within the first 6 hr after drug administration and formed a painless oedema around the base of the ear. The swelling decreased in all affected individuals within 24 hr and disappeared or was significantly reduced towards the end of the study, after 72 hr.
| Pharmacokinetic analysis
All data are reported as geometric means (Gmean) and standard error of the mean (±SEM). After the single i.m. injection of 1 mg/ kg, a carprofen concentration of 0.088 ± 0.11 μg/ml was reached after 4.68 ± 0.54 min. The maximum carprofen concentration (C max ) of 5.77 ± 0.63 μg/ml was reached after 9.51 ± 3.53 hr. At the time of the last blood draw, after 73.07 ± 0.63 hr, carprofen plasma concentrations were still at 3.69 ± 0.2 μg/ml. Carprofen half-life of λ z was estimated at 105.71 ± 15.67 hr and the mean residence time (MRT) in plasma at 155.01 ± 22.46 hr. The area under the curve extrapolated to infinity (AUC tot ) was 904.61 ± 110.78 μg ml −1 hr −1 .
The mean clearance of carprofen was 0.0011 ± 0.0001 L hr
The apparent volume of distribution at steady-state and at terminal phase was 0.17 ± 0.01 L/kg. The pharmacokinetic parameters for all individuals are summarized in Table 2 . The carprofen plasma concentration-time curve for each individual is shown in Figure 1 , the average plasma concentration-time curve and the standard error of the mean for all individuals are presented in Figure 2 .
| Pharmacodynamic analysis
TXB 2 plasma concentrations were determined by ELISA and were characterized by high inter-animal differences (Figure 1) . In all TA B L E 2 Pharmacokinetic parameters of carprofen in six white rhinoceros after single intra muscular injection of 1 mg/kg λ, terminal elimination rate constant; t 1/2 , half-life; C max , maximum plasma concentration; T max , time to maximum plasma concentration; AUC last , area under the curve until the last time point; AUC tot , area under the curve extrapolated to infinity; AUC extra , area under the curve from the last quantifiable measurement to infinity; AUCM last , area under the moment curve from t = 0 to the last measured time point; Cl/F, clearance corrected for bioavailability; V z /F, apparent volume of distribution during the terminal phase corrected for bioavailability; V ss /F, apparent volume of distribution in steady-state corrected for bioavailability; MRT, mean residence time.
individuals, TXB 2 concentrations increased after carprofen administration and reached a peak concentration after 22.3 ± 18.46 min.
The mean carprofen plasma concentration at the time of the peak was 0.6 ± 0.59 μg/ml. In rhino I, II and III the TXB 2 activity decreased rapidly after reaching the peak and remained around the initial TXB 2 concentration measured prior to the administration of carprofen. In rhino IV, the TXB 2 concentration continuously decreased after 22.02 hr until the end of the study (72.57 hr). In contrast, while the TXB 2 activity in rhino V and VI decreased after reaching the peak concentration, TXB 2 concentrations started to increase again after 11.88 hr (rhino V) and 11.32 hr (rhino VI) until the end of the study. The carprofen plasma concentration versus time profiles, as well as the TXB 2 versus time profiles for each individual and as the Gmean (±SEM) of all individuals, are depicted in Figures 1 and 2 , respectively.
| D ISCUSS I ON
Carprofen, a drug with antipyretic, anti-inflammatory and anal- Carprofen was characterized by a fairly long absorptive phase with a T max of 9.51 ± 3.53 hr (corresponding C max of 5.77 ± 1.55 μg/ ml). The absorptive phase compares favourably with the horse, which exhibits a comparable T max of 10.6 ± 1.6 hr, albeit at a lower maximum concentration of 2.2 ± 0.4 μg/ml following a single dose of 0.7 mg carprofen/kg (McKellar et al., 1991) . While we did not specifically evaluate the reason for the slow absorption of the drug from the site of injection, we believe that it may be attributed to , 1991) . From pharmacokinetic theory, is it known that localized irritation at the administration site can slow absorption (McKellar et al., 1991) , which is used in formulation chemistry to create long-lasting effects for certain antibiotic formulations (Xia, Gyrd-Hansen, & Nielsen, 1983) . The second reason for the slow absorption may be a drug interaction between etorphine and carprofen. From previous studies, vasoconstrictive effects have been reported following etorphine administration in both rhino and goats (Heard, Nichols, Buss, & Kollias, 1996; Heard, Olsen, & Stover, 1992) . As such, the change in blood supply to the site of administration may be responsible for the delayed absorptive phase. Of the two causes, the latter is more likely, as no injection site reactions were visible clinically in any of the treated animals.
Another major finding for this study is the exceptionally long half-life of 105.71 ± 15.67 hr with large inter-animal variability.
The half-life in the white rhino is substantially longer than the 29.4 ± 3 hr following a single i.m. dose at 0.7 mg/kg in the horse (McKellar et al., 1991) ; or the 30.7 ± 2.3 hr in the cow (Lohuis et al., 1991) and 26.1 ± 1.1 hr in sheep (0.7 mg/kg IV; Welsh et al., 1992) . To our knowledge, the half-life in the white rhinoceros is the longest recorded half-life amongst all mammalian species. This in itself is not a very surprising finding, as previous studies we have undertaken with enrofloxacin have also shown the rhino to be a slow metabolizer, even when their size is taken into consideration. As a result, we speculate that the rhino is metabolically Vancutsem & Babish, 1996) . While enrofloxacin seems to increase the half-life of elimination of theophylline, the effect on the metabolism of NSAIDs seems to be less consistent (Intorre et al., 1995) . Flunixin in conjunction with enrofloxacin (5 mg/ kg s.c.) in dogs leads to a significant increase in the elimination half-life by 29% (Ogino et al., 2005) ; while the administration of diclofenac with enrofloxacin in sheep results in a slowed absorption and a prolonged elimination half-life (57%; Rahal et al., 2008) .
In contrast, in calves, enrofloxacin induces a 27% decrease in the half-life of elimination of flunixin (Abo-El-Sooud & Al-Anati, 2011) . In horses, however, the concomitant administration of enrofloxacin at a dose of 5 mg/kg with firocoxib does not change the pharmacokinetics of firocoxib (Cox et al., 2012) . With specific information on interaction of fluoroquinolones and carprofen currently unavailable, it is difficult to establish if the long half-life of carprofen results from an interaction or a general metabolic constraint in the rhinoceros. Nonetheless, based on the extremely long half-life of carprofen in the rhino, enzyme inhibition alone would probably not explain the latter. To definitely answer this question, the pharmacokinetics of carprofen would need to be established in a single drug study.
To evaluate the duration of benefits of carprofen, we assessed its effects on TXB 2 plasma concentrations. In general, the NSAIDs are known to, in part function through the inhibition of the cyclooxygenase 1 and 2 (COX-1 and 2) leading to a reduced production of eicosanoids and as a result, inhibiting inflammatory reactions, pain and hypersensitivity (Moses & Bertone, 2002) . The constitutively expressed COX-1 plays a less significant role in cases of tissue injury and inflammation than COX-2, however, increases by 2-to 3-fold after tissue injuries and plays a role in pain transmission (Brooks et al., 1999) . In contrast, COX-2 enzymes are induced and upregulated during inflammatory processes and in case of tissue damage.
Their concentrations can raise 20-fold above the baseline values (Brooks et al., 1999; Lee et al., 1992) .
To assess the degree of COX-1 inhibition of NSAIDs, TXB 2 is commonly used as a surrogate marker (Lees et al., 2004) .We were expecting TXB 2 to decline as described in species such as the horse and the cat (Lees, McKellar, May, & Ludwig, 1994; Taylor et al., 1996) . In horses, studies demonstrated a moderate inhibition of TXB 2 at low doses of carprofen (0.7 mg/kg) and complete inhibition at high carprofen doses (4 mg/kg; Lees et al., 1994 Lees et al., , 2002 . However, as with field-type trials, we experienced an unexpected adverse reaction for the concurrently administered enrofloxacin. The enrofloxacin administration caused a visible, localized adverse reaction in four of six rhinoceros (rhino I, III, IV, VI). It manifested in the form of a band like swelling at the base of the ear in which enrofloxacin was injected. This was evident in the plasma, as a rapid increase in TXB 2 concentrations with the peak of activity after 22.3 ± 18.46 min (TXB 2 ), which was followed by a rapid decline. Using this unexpected reaction, we are able to provide an indication of the expected duration of effect of carprofen. Firstly, the early decline of the TXB 2 concentration after 22.3 ± 18.46 min indicates a rapid onset of effect of carprofen, which is consistent with the results from a study by Borer, Peel, Seewald, Schawalder, and Spreng (2003) . Using an acute synovitis model, Borer et al. (2003) assessed the analgesic and antiinflammatory properties of carprofen in dogs and recorded an analgesic effect after 2.6 hr.
Besides assessing the plasma drug concentration, an important consideration when looking at the duration of effect of the NSAIDs is the duration of enzyme inhibition. Studies by Lees et al. (1994) in horses have shown no identifiable relationship between the carprofen plasma concentration and the effect on the COX enzymes. This has led to the concept of a pharmacodynamic half-life, which describes the relation between the effect (E) of a drug and the time (t).
A mathematical relationship can be established between the pharmacokinetic and pharmacodynamic half-life and shows that for high drug concentrations, the pharmacodynamic half-life is considerably longer than the pharmacokinetic half-life, leading to a longer lasting drug effect (Keller, Czock, Zellner, & Giehl, 1998) . As an example, the concept of the pharmacodynamic half-life could explain why carprofen in dogs exhibits a relatively short half-life of 7.99 ± 2.89 hr, while its postsurgical analgesic effect lasts for about 24 hr (McKellar et al., 1990; Shih, Robertson, Isaza, Pablo, & Davies, 2008) . Based on the effective concentration and the secondary peak of TXB 2 production in rhino V and VI after 48 hr, we believe that the drug would be effective for a minimum of 48 hr after single carprofen administration. Nonetheless, these results have to be assessed with caution as the interpretation of the data is complicated by the lack of obvious correlation between the degree of TXB 2 inhibition and carprofen plasma concentrations, as described by Lees et al. (1994) in the horse.
While we are confident of the anti-inflammatory effect of carprofen in white rhino, we cannot conclusively show that it will be effective as an analgesic. To try to ascertain the value of the pharmacokinetic parameters, the concentrations achieved were compared to results from Schatzmann et al. (1990) who assessed the peripheral pain inhibition of carprofen in horses. Using the heating element model, the study demonstrated that 0.7 mg carprofen/mg successfully inhibited pain for roughly 24 hr. The analgesic effect of carprofen was correlated to a plasma concentration of at least 1.5 μg/ml. When comparing the effective carprofen plasma concentration of at least 1.5 μg/ml in the horse to the rhino pharmacokinetic profile, the plasma concentration of 1.5 μg/ml was achieved as early as 31 ± 0.98 min after carprofen administration and was maintained beyond the 72-hr monitoring period, with the carprofen plasma concentration still above 3.68 ± 0.2 μg/ml. While we suggest that actual pain monitoring needs to be conducted in rhino treated with carprofen, we would expect the drug to be effective in most animals for a minimum of 48 hr.
| CON CLUS ION
Wildlife veterinarians have documented good analgesic effects when using carprofen in injured white rhinoceros in the field (personal communication, Dr. Johan Marais, Saving the Survivors). To scientifically evaluate carprofen for a safe and efficient application in white rhinoceros, this first of its kind study investigated the pharmacokinetic and pharmacodynamic properties after a single dose injection.
We were able to demonstrate that the pharmacokinetic profile of carprofen in rhinoceros differed significantly from that of the horse and any other species. Carprofen was characterized by a remarkable long half-life of λ:z, which is longer than the reported half-lives in any mammalian species. Based on the evaluation of the surrogate marker TXB 2 , the drug also appeared to be anti-inflammatory for a minimum of 48 hr after administration in most animals, making it a promising drug to consider and further evaluate for the management of pain and inflammation in white rhinoceros.
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